Publisher： Bentham Science Publishers
E-ISSN： 1873-4286|18|8|1159-1169
ISSN： 1381-6128
Source： Current Pharmaceutical Design, Vol.18, Iss.8, 2012-03, pp. : 1159-1169
Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.
Abstract
Nonhuman primates are useful for the study of age-associated changes in the brain and behavior in a model that is biologically proximal to humans. The A&bgr; and tau proteins, two key players in the pathogenesis of Alzheimer's disease (AD), are highly homologous among primates. With age, all nonhuman primates analyzed to date develop senile (A&bgr;) plaques and cerebral &bgr;-amyloid angiopathy. In contrast, significant tauopathy is unusual in simians, and only humans manifest the profound tauopathy, neuronal degeneration and cogni-tive impairment that characterize Alzheimer's disease. Primates thus are somewhat paradoxical models of AD-like pathology; on the one hand, they are excellent models of normal aging and naturally occurring A&bgr; lesions, and they can be useful for testing diagnostic and therapeutic agents targeting aggregated forms of A&bgr;. On the other hand, the resistance of monkeys and apes to tauopathy and AD-related neurodegeneration, in the presence of substantial cerebral A&bgr; deposition, suggests that a comparative analysis of human and nonhuman primates could yield informative clues to the uniquely human predisposition to Alzhei 's disease.
Related content
Non-Human Primate Models for AIDS Vaccine Research
Current Drug Targets - Infectious Disorders, Vol. 5, Iss. 2, 2005-06 ,pp. :
Access to resources
Recommend
CNS & Neurological Disorders - Drug Targets (Formerly Current Drug Targets - CNS & Neurological Disorders), Vol. 12, Iss. 8, 2013-12 ,pp. :
By Bading James R. Yamada Shinya Mackic Jasmina B. Kirkman Linda Miller Carol Calero Miguel Ghiso Jorge Frangione Blas Zlokovic Berislav V.
Journal of Drug Targeting, Vol. 10, Iss. 4, 2002-01 ,pp. :